Stay updated with the latest news and analysis on RoAdevar.
On 18 September the FDA granted Priority Review to the application for efzimfotase alfa, an investigational treatment from Alexion, AstraZeneca’s rare...
Useful Sections
Cookie preferences
Choose optional categories. Essentials stay on for normal operation and security of the site.
Essential
Always onRequired for the site to work securely and as intended (e.g. session, forms, account). Without them, parts of the site may not work correctly.
Preferences
OptionalRemember comfort settings longer when applicable. The site still works without them.
If refused, you can set options again later. Account and browsing do not depend on this category.
Analytics (Google)
OptionalAllows Google Tag Manager / Analytics style traffic measurement where configured. Not required to read the site.
If refused, Google analytics tools do not load. Content, account and forms stay available.
Marketing
Not available right nowCookies for personalised ads or remarketing when enabled on the platform.
Personalised advertising is not active on the site in its current form.
What stays available
You can read news, browse, use your account and forms whether you accept or refuse optional cookies.
How long it lasts
Choices are kept on the device for about 12 months or until you change them. When signed in, they are linked to your account for the current device.
